Lynparza/Recentin Combo Fails In Phase III PSR Ovarian Cancer
Disappointment For AstraZeneca
Lynparza will weather the failure of the Phase III GY004 study, but VEGF inhibitor Recentin’s future looks even less certain; other studies of the combination continue.
You may also be interested in...
Two new PARP inhibitor studies – GSK’s PRIMA and AstraZeneca/Merck & Co.’s PAOLA-1 – are set to widen the ovarian cancer market after they reported highly positive first-line results in advanced patients at ESMO.
Lynparza will be the first PARP inhibitor cleared for maintenance treatment to extend response to first-line chemo, but in BRCA mutant patients – while Tesaro/GSK should have Phase III results for Zejula monotherapy in all-comers in 2019.
The impact of the coronavirus pandemic on the size of the pharma R&D pipeline in 2020 could be felt in a number of ways.